These findings suggest that even a single, low-fluence 670 nm exposure can acutely support cone function in older eyes, consistent with rapid mitochondrial and bioenergetic modulation.
Absorption of photon energy by neuronal mitochondria leads to numerous downstream neuroprotective effects.
670 nm light upregulated cytochrome c oxidase and reduced retinal inflammation, providing mechanistic foundation for clinical AMD PBM outcomes.
PBM using 670 nm combined with lower-fluence 590/790 nm exposure demonstrated clinically meaningful and statistically significant improvements in visual function, with benefits persisting up to one year.
the findings highlight that mitochondria-responsive wavelengths in the red/NIR range can drive functional benefits in retinal tissue when delivered within safe fluence windows.
This foundational study characterized mitochondrial structural/functional deficits in AMD RPE, establishing mitochondrial dysfunction as a key therapeutic target for PBM.
These findings reinforce the concept that mitochondrial-targeted photobiomodulation can partially reverse age-related retinal decline and may have implications for managing retinal aging and age-related disease such as AMD.
Red and near-infrared wavelengths (650–800 nm) were shown to activate cytochrome c oxidase (Complex IV), increase ATP production, and promote mitochondrial resilience. In ischemic RGC models, additional long-wavelength light exposure preserved mitochondrial function and improved cellular survival.
These results connect systemic immune modulation with retinal mitochondrial health and inflammatory load—two major contributors to age-related macular degeneration (AMD) progression.
PBM showed visual acuity improvements and drusen reduction in dry AMD through multi-pathway mechanisms.
